MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsClinical EvidenceGlobal MarketsePRO

    Electronic Patient-Reported Outcome

    A patient-reported outcome instrument administered and captured electronically, subject to validation and 21 CFR Part 11 data-integrity requirements when used in FDA-regulated trials.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026

    Definition

    ePRO refers to the electronic capture of patient-reported outcome data, such as symptom diaries, quality-of-life questionnaires, or pain scales, using tablets, smartphones, web portals, or other electronic systems instead of paper forms. FDA's 2009 guidance on patient-reported outcome measures, and subsequent methodology discussion papers, describe expectations for developing a PRO instrument's content validity and for demonstrating that migrating an existing paper instrument to an electronic modality does not change how patients interpret or respond to it, an activity commonly called equivalence or migration testing. When ePRO data are used to support a medical product labeling claim or a device's clinical evidence, the electronic system that captures, stores, and transmits the data must comply with 21 CFR Part 11 requirements for electronic records and electronic signatures, including audit trails, access controls, and record retention.
    What the regulation says
    FDA's Guidance for Industry on Patient-Reported Outcome Measures states that if a PRO instrument is modified, including a change in mode of administration such as from paper to electronic, evidence should be provided that the modified instrument still adequately measures the concept of interest, generally through cognitive interviewing or equivalence testing rather than a full re-validation in every case.

    What this means in practice

    ePRO adoption has grown alongside decentralized and hybrid clinical trials, since electronic capture reduces missing data and enables real-time compliance monitoring, but it also raises data integrity questions that regulators scrutinize during inspection. ICH E6(R3), the revised Good Clinical Practice guideline, expands expectations for data governance, including for data generated through electronic patient-facing systems, aligning international expectations with FDA's Part 11 framework.
    Common pitfalls
    • •Migrating a paper PRO instrument to a tablet or app without conducting equivalence testing, which can invalidate the instrument's established measurement properties.
    • •Deploying an ePRO platform that lacks a compliant audit trail or that allows undocumented edits to submitted patient responses, creating a Part 11 data integrity finding.
    • •Assuming ePRO always improves compliance; poor usability or connectivity gaps in a decentralized trial can increase missing data if the platform is not tested with the intended patient population.

    Frequently asked questions

    Not necessarily. FDA guidance allows a tiered approach where minor modality changes may require only usability and equivalence testing, while substantive changes to item wording or response options may require broader re-validation.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2
    Link health: 3 verified· last checked 2026-06-20
    FDA·1eCFR·1ICH·1
    1. 1
      FDA Guidance, Patient-Reported Outcome Measures
      Tier 2 Verified
      FDAfda.gov
    2. 2
      21 CFR Part 11, Electronic Records; Electronic Signatures
      Tier 1 Verified
      eCFRecfr.gov
    3. 3
      ICH E6(R3) Good Clinical Practice
      Tier 2 Verified
      ICHich.org

    Inline markers like [1] jump to the matching reference above.